drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular therapy, CAR T cells)
drug_description
Autologous dual-target CAR T-cell therapy in which the patient’s T cells are engineered to express chimeric antigen receptors recognizing BCMA and GPRC5D; administered by IV infusion to activate T-cell cytotoxicity against multiple myeloma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express dual chimeric antigen receptors targeting BCMA and GPRC5D on myeloma cells; antigen binding triggers CAR signaling (CD3 zeta with co-stimulation), activating T-cell cytokine release and perforin/granzyme-mediated cytotoxic killing, with dual targeting intended to reduce antigen escape.
drug_name
OL-101
nct_id_drug_ref
NCT06644118